Dexcom Inc. is a leading medical device company focused on the development and commercialization of continuous glucose monitoring (CGM) systems for people with diabetes. Its mission is to empower individuals to manage their diabetes more effectively through innovative technology that provides real-time glucose data. Dexcom's strategy emphasizes research and development to enhance its product offerings, expand market reach, and improve patient outcomes. The company's operations involve the design, manufacturing, and distribution of CGM devices that enable users to monitor their glucose levels seamlessly, ultimately aiming to improve the quality of life for those living with diabetes.

DEXCOM INC

DexCom is making notable advancements in diabetes management technology with several key developments impacting the investing landscape. In March 2024, the FDA approved the Dexcom Stelo Continuous Glucose Monitor, the first over-the-counter device designed specifically for self-monitoring glucose levels in non-insulin-dependent patients, which reflects the rising demand for such tools...

DexCom Launches First Generative AI Platform for Glucose Monitoring and Receives FDA Approval for Innovative Stelo CGM Device.